Cargando…

Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens

Genotyping BRAF in melanoma samples is often challenging. The presence of melanin greatly interferes with thermostable DNA polymerases and/or nucleic acids in traditional polymerase chain reaction (PCR)-based methods. In the present work, we evaluated three easy-to-use strategies to improve the dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frouin, Eric, Maudelonde, Thierry, Senal, Romain, Larrieux, Marion, Costes, Valérie, Godreuil, Sylvain, Vendrell, Julie A., Solassol, Jérôme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965116/ https://www.ncbi.nlm.nih.gov/pubmed/27466810 http://dx.doi.org/10.1371/journal.pone.0158698

Ejemplares similares

Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing
por: Marchant, Julie, et al.
Publicado: (2014)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

Cutaneous Epithelial Tumors Induced by Vemurafenib Involve the MAPK and Pi3KCA Pathways but Not HPV nor HPyV Viral Infection
por: Frouin, Eric, et al.
Publicado: (2014)

High-throughput detection of clinically targetable alterations using next-generation sequencing
por: Vendrell, Julie A., et al.
Publicado: (2017)

Determination of the Optimal Bacterial DNA Extraction Method to Explore the Urinary Microbiota
por: Vendrell, Julie A., et al.
Publicado: (2022)

KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues
por: Solassol, Jérome, et al.
Publicado: (2011)

Circulating Cell Free Tumor DNA Detection as a Routine Tool for Lung Cancer Patient Management
por: Vendrell, Julie A., et al.
Publicado: (2017)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting
por: Mourah, Samia, et al.
Publicado: (2015)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens
por: Løes, Inger Marie, et al.
Publicado: (2014)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer
por: Vendrell, Julie A., et al.
Publicado: (2019)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches
por: Vendrell, Julie A., et al.
Publicado: (2017)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Proteomic profile determination of autosomal aneuploidies by mass spectrometry on amniotic fluids
por: Mange, Alain, et al.
Publicado: (2008)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
por: Kocovski, Linda, et al.
Publicado: (2015)

BRAF V600 mutations and pathological features in Japanese melanoma patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
por: Zepeda-Lopez, Priscilla Denise, et al.
Publicado: (2016)

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma
por: Banzi, Maria, et al.
Publicado: (2016)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Activation of the Mitochondrial Fragmentation Protein DRP1 Correlates with BRAF(V600E) Melanoma
por: Wieder, Shira Y., et al.
Publicado: (2015)

Impact of BRAF(V600E) mutation on aggressiveness and outcomes in adult clonal histiocytosis
por: Razanamahery, Jerome, et al.
Publicado: (2023)

The clinical response to vemurafenib in a patient with a rare BRAF(V600DK601del) mutation-positive melanoma
por: Trudel, Stéphanie, et al.
Publicado: (2014)

Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib
por: Ross, Kayleigh C., et al.
Publicado: (2018)

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF(V600) melanoma
por: Smith, Lorey K., et al.
Publicado: (2022)

BRAF(V600E )mutations in malignant melanoma are associated with increased expressions of BAALC
por: Schrama, David, et al.
Publicado: (2008)

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets
por: Improta, Giuseppina, et al.
Publicado: (2013)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma
por: Ruiz-Garcia, Erika, et al.
Publicado: (2017)

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
por: Krepler, Clemens, et al.
Publicado: (2016)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_821lc5qo1321kbnt2017gjc1q3